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ARTICLE
Assessing the impact of imperfect adherence to
artemether-lumefantrine on malaria treatment
outcomes using within-host modelling
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Artemether-lumefantrine (AL) is the most widely-recommended treatment for uncompli-
cated Plasmodium falciparum malaria worldwide. Its safety and efﬁcacy have been extensively
demonstrated in clinical trials; however, its performance in routine health care settings, where
adherence to drug treatment is unsupervised and therefore may be suboptimal, is less well
characterised. Here we develop a within-host modelling framework for estimating the effects
of sub-optimal adherence to AL treatment on clinical outcomes in malaria patients.
Our model incorporates the data on the human immune response to the parasite, and
AL’s pharmacokinetic and pharmacodynamic properties. Utilising individual-level data of
adherence to AL in 482 Tanzanian patients as input for our model predicted higher rates of
treatment failure than were obtained when adherence was optimal (9% compared to 4%).
Our model estimates that the impact of imperfect adherence was worst in children, high-
lighting the importance of advice to caregivers.
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The malaria parasite has thrived for millennia
1. Despite
concerted efforts, which have considerably reduced the
burden of mortality and morbidity in recent years, in
2015 this parasite was still responsible for an estimated 212
million clinical cases and 429,000 deaths2. Artemisinin-based
combination therapies (ACTs) are the ﬁrst-line treatments for
uncomplicated cases of Plasmodium falciparum3. The artemisinin
derivative rapidly kills parasites, but is eliminated quickly by the
body. Its partner drug has a longer half-life and clears parasites
that remain after the artemisinin has been eliminated. ACTs have
been instrumental in reducing malaria burden4. The majority of
endemic areas have little or no drug resistance to ACTs and their
high efﬁcacy (~95%) at clearing parasitaemia has been extensively
demonstrated in clinical trial settings5,6. However, there is less
information on ACT effectiveness in routine health care settings
when treatment is not supervised. Understanding how real-life
patterns of patient adherence alter effectiveness, and how these
can be improved is critical to maximising the role of ACTs in
combating malaria.
Artemether-lumefantrine (AL) is the most widely administered
antimalarial globally, being the ﬁrst or second-line treatment in
30 countries in Africa, 10 in the Americas, 2 in the Eastern
Mediterranean, 6 in South-East Asia, and 5 in the Western
Paciﬁc, as of 20152. In 2013, it represented 73% of antimalarials
procured worldwide7. The recommended course of treatment is 6
doses to be taken over 3 days, in contrast to the other ACTs
currently recommended by the World Health Organisation which
have only 3 doses taken over 3 days3. The increased number of
doses has raised concerns about whether patient adherence to AL
may be a problem in routine health settings.
Adherence to treatment can be assessed in a number of ways,
including self-report by the patient or care giver, counting
any pills remaining after treatment, measuring the timing of
doses electronically or estimating doses taken by measuring drug
concentrations present in the blood8,9. Measured patient adher-
ence to AL varies from under 50 to 100%, dependent on setting
and deﬁnition of adherence9. It is not easy to ascertain the effects
of imperfect adherence on treatment outcomes. This can be
studied indirectly by assessing the efﬁcacy of supervised treatment
compared with unsupervised treatment. Rahman et al. found
that efﬁcacy of treatment was high for both supervised and
unsupervised patients in Bangladesh10. Studies of unsupervised
usage of AL in Papua New Guinea have showed conﬂicting
results11,12. In young Tanzanian children treated with AL, high
cure rates were reported in supervised- and unsupervised-
treatment groups; however, the median blood concentration of
lumefantrine was lower in the unsupervised group, suggesting
suboptimal adherence13.
While these studies are informative, due to the complexity of
adherence behaviour that varies not just by number of doses
taken but also by timing, it is not possible from the above studies
to identify which aspects of adherence are most important to
ensure treatment success. The number of patients with any
speciﬁc type of non-adherent treatment pattern in each study
is small, and it is difﬁcult to infer relationships from multiple
studies due to varying degrees of immunity, which inﬂuences
treatment success.
Given these challenges, there is scope for mathematical
modelling work to complement the studies described above.
A number of models combine a description of the within-host
dynamics of parasitaemia with the pharmacokinetics (PK) and
pharmacodynamics of antimalarial drugs14–20. Models describing
within-host parasitaemia, are either simple and focus on the onset
of a malaria infection15,17–19, or more complicated and char-
acterise the whole infection, including the immune response
mounted against the parasite19,20. Typically, these models assume
full adherence to treatment. A previous study modelled the effects
of imperfect drug adherence on treatment failure, ﬁnding that
treatment efﬁcacy for AL was quite robust to skipping or delaying
doses15. However, this model did not incorporate immune
responses, which inform longer-term dynamics of recrudescent
infections. The most detailed information on the parasite
dynamics and the response of the human immune system is from
a study of patients with neurosyphilis who were infected with
P. falciparum as treatment for the bacterial infection. This
“malaria therapy” data set provides an opportunity to study
untreated infections of P. falciparum malaria21, and has informed
many within-host models21–27. Antigenic variation in the parasite
population leads to complex within-host dynamics28,29 and must
be considered in models of the whole course of untreated
P. falciparum infections.
Here we model the impact of imperfect patient adherence to
AL using a multi-faceted approach. We develop a model of
an untreated P. falciparum infection within the human host,
simplifying parasite dynamics to a single equation, while keeping
good ﬁdelity to the data and still reproducing the effects of
antigenic variation. We utilise an existing population PK model
and calibrate a pharmacodynamic model to match observed
recrudescence rates in clinical trials of AL, where treatment is
supervised. We then model the effects of imperfect drug adher-
ence on patients’ clinical outcomes, utilising the data on patient
adherence to AL collected in Tanzania. When we use these data
Table 1 Comparing the model output with the malaria therapy data set
Minimum value Median value Maximum value
Initial slope: increase in log10 parasitaemia per day 0.24 0.19 0.25 0.51 0.49 0.49 0.75 0.87 0.71
Number of local peaks in parasitaemia 2 2 1.7 9 10 7.7 17 17 15.5
Slope of successive local peaks in parasitaemia −0.091 −0.074 −0.03 −0.015 −0.013 −0.010 −0.007 −0.001 −0.002
Log10 of parasite density at 1st peak 3.69 3.37 3.57 4.78 4.79 4.77 5.67 5.66 5.61
Geometric mean of intervals between peaks in parasitaemia 1.5 14.4 12.2 14.6 20.0 22.8 28.4 77.8 61.0
Last day of patent parasitaemia 38 37 39 193 215 198 404 405 409
Proportion of parasite-positive observations in 1st half of infection 0.57 0.4 0.46 0.97 0.88 0.97 1.0 1.0 1.0
Proportion of parasite-positive observations in 2nd half of infection 0.12 0.08 0.10 0.58 0.46 0.79 1.0 1.0 1.0
Standard deviation of the log of the intervals between consecutive local
peaks
0.04 0.03 0.03 0.31 0.2 0.22 0.56 0.47 0.48
Here we display the values of the nine summary statistics describing dynamics of untreated infections in the malaria therapy data used to ﬁt the model, as in ref. 30. The central values are the data, values
on the left (italics) are best-ﬁt values from the model by Johnston et al., and values on the right (bold) are the best-ﬁt values for our model (see Supplementary Methods for details and a description of
the summary statistics). All quantities are based on parasitaemia detectable via microscopy. A local peak in the parasitaemia was deﬁned as a parasite density greater than the three previous model
observations, and greater than or equal to the next three observations. The ﬁrst and second halves of the infection are deﬁned via the ﬁrst and last days that the patient was parasite positive by
microscopy
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to determine the timings of doses in our simulation model, we
obtain a model-estimated failure rate of 9%. If we assume perfect
adherence here, the model-estimated failure rate is only 4%,
which highlights the impact imperfect adherence to treatment can
have on patient outcomes.
Results
Dynamics of untreated Plasmodium falciparum infections.
First, we developed a stochastic model to capture the dynamics of
an untreated P. falciparum infection. Including long-term as well
as short-term dynamics of parasitaemia is important to inform
realistic predictions about recrudescent infections. Our starting
point was a model by Johnston et al.30, which built on existing
work by Molineaux et al.21. Following their approach, we model
three immune responses mounted by the host: the innate (fever)
response, a variant-speciﬁc antibody-mediated response and a
general antibody-mediated response. However, in contrast to
previous work, we adapted the model to describe total asexual
parasitaemia rather than separate subpopulations of var variants,
resulting in a more computationally efﬁcient model with one
equation rather than 50. The simpler framework presented two
challenges: how to describe the ﬂuctuating growth rates caused by
antigenic switching, and how to capture the interactions between
the immune response and changes in parasite var presentation.
To calibrate our model, we followed the approach of Johnston
et al. who ﬁtted to the minimum, median and maximum values of
nine summary statistics, which describe the dynamics of infec-
tions in the malaria therapy data (Table 1), such as the duration
of observed infection, and the rate of increase in parasite density
at the beginning of the infection (see ‘Methods’ section).
The observed variation in parasite growth rate over the course
of the infection (modelled as a variant-speciﬁc trait in ref. 25)
could be reproduced using a growth rate which varies
stochastically over time but is correlated with the growth rate
in the previous time point. Variant-speciﬁc immunity was
approximated by an immune response which had limited
memory of past parasitaemia, to mimic the parasite antigenic
variation (see ‘Methods’ section). The structural form of our ﬁnal
model is displayed in Eq. 1 (see ‘Methods’ section) and Fig. 1a
shows simulated parasitaemia over time in three example patients
from the best-ﬁt model (Supplementary Table 1). In general, we
obtain a good ﬁt to the target summary statistics (Table 1), with
our new model describing aspects of both the initial acute phase
of infection and later stages of infection well, including the ﬁrst
wave of parasitaemia, the decline in successive peaks of parasite
density the duration of infection and the variation in these
between patients. The model overestimates the proportion of
observations where parasitaemia was above the microscopy
threshold during the later stages of infection, although more
complicated models have also struggled to capture this24.
Population PK-pharmacodynamic model. We modelled the
impact of AL on parasitaemia in each patient, simulating blood
drug concentrations using a published PK model26, and esti-
mating pharmacodynamic parameters using the clinical trial data.
The published PK model was previously ﬁtted to the data from
adults and children in Tanzania treated with AL for clinical
episodes of uncomplicated falciparum malaria31 and includes
both the effect of body weight and population-level variation in
PKs (Supplementary Fig. 2). This model also describes the con-
centrations of the active metabolites of both artemether and
lumefantrine, dihydroartemisinin (DHA) and desbutyl-
lumefantrine (DLF), respectively. We modelled the standard
course of AL, which requires twice-daily doses for 3 days (see
‘Methods’ section for recommended dose timings).
Time between infection and treatment was modelled by using a
previously-deﬁned pyrogenic threshold (the parasite density at
which fever commences) which varies signiﬁcantly between
patients32, and combining this with a distribution of times
subsequently taken to seek treatment using self-reported times
obtained from Demographic and Health Surveys33 in sub-
Saharan Africa (see Supplementary Methods).
Whereas the PK properties of the antimalarial drugs can be
measured directly through the concentrations of the drugs in the
blood, the pharmacodynamic properties of the drugs must be
inferred from their effects on the parasitaemia. To do this, we
matched treatment outcomes to the data from a clinical trial in
which AL was used to treat uncomplicated falciparum malaria in
children in Ndola, Zambia. The low prevalence of falciparum
malaria in this region at the time of the study4 suggests that these
children should have low levels of naturally acquired immunity.
In the trial, all doses were administered under direct supervision,
to ensure adherence to treatment was optimal. We simulated
a cohort of patients with a body weight distribution consistent
with the study population6. We ﬁt our PD model (Eq. 7) to
two metrics: the proportion of parasite-positive patients at day 1
(i.e., 24 h after the ﬁrst dose was administered), and the PCR-
corrected recrudescence rates at day 28 (see ‘Methods’ section).
Both these outcomes were required to determine the best-ﬁt PD
parameters, which are given in the ‘Methods’ section. Figure 1b
illustrates the impact of treatment in our simulations, including
some cases where the antimalarials do not clear the parasite
population. For the body-weight distribution used to ﬁt the
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Fig. 1 Simulated parasitaemia within individual patients. Here we show example model output for the parasite density (the number of parasitised red blood
cells per µL) over time. Our within-host parasitaemia model was ﬁtting to data from 35 malaria therapy patients, as described in the ‘Methods’ and
Supplementary Methods section. a Untreated infections, where each different coloured line represents a different patient. These three model simulations
were selected to demonstrate the variety of infection duration generated by the model. b Treated infections in 1000 simulated patients treated with six
doses of AL, with the median parasitaemia at each two-day time point shown in black. Treatment fails in about 5% of cases (here coloured blue), causing
patients to relapse
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model, about 5.7% of simulated patients failed treatment (deﬁned
as the presence of a microscopy-detectable infection at day 28).
Factors inﬂuencing treatment failure. Population-level variation
in PKs leads to wide variation in drug concentrations, even when
all doses are supervised (Supplementary Fig. 2). In our simula-
tions of perfectly-adherent patients (i.e., all doses contained the
correct number of pills, and were taken at precisely the
recommended timings), low blood concentration of lumefantrine
on day 7 after treatment, particularly <100 ng/ml, is strongly
associated with increased probability of treatment failure
(Fig. 2a), here deﬁned as being parasite-positive by microscopy on
day 28. This matches well with previous clinical trial observa-
tions34,35. We estimate that in perfectly-adherent patients who
fail treatment, the median time to becoming microscopy-positive
is 21 days (Fig. 2b). We ﬁnd that a follow-up at 28 days will detect
the majority of treatment failure events (93%), and therefore use
this treatment failure outcome for our analysis. However, in
clinical trial settings, this could indicate that a later follow-up may
detect additional recrudescences in a cohort of patients.
A patient’s body weight affects the concentration of antimalar-
ials in the blood and hence those at the low end of a dosing group
have higher concentrations than at the high end. For example, by
the dosing guidelines (see ‘Methods’ section), a patient weighing
14 kg will receive one tablet per dose, while a patient weighing
16 kg will receive two. In a simulated population of adults and
children with varying body weight, we ﬁnd variation in the
probability of treatment failure with the patient’s body weight
(Fig. 2c). We estimate only a small effect in most body-weight
categories, but a more substantial effect in the 5–15 kg category,
causing an estimated ~4% difference in efﬁcacy between the
smallest and largest body weight. The average efﬁcacy is predicted
to improve overall with age due to the effect of body weight on
PKs, even without acquired immunity. We repeated this analysis,
including an additional follow-up at 42 days. These results are
also shown in Fig. 2a, c.
The impact of imperfect drug adherence on treatment out-
comes. We used the calibrated model to estimate the con-
sequences of imperfect adherence to treatment. One reason for
poor adherence may be that, if symptoms are alleviated after the
ﬁrst few doses, the patient may not complete the treatment
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Fig. 2 Details of treatment failure in our within-host model. Here we summarise simulated data generated from the proportion (about 5%) of 106 model
runs for which treatment failed. a The estimated probability of parasitological treatment failure according to the lumefantrine concentration 7 days after
treatment commenced. The proportion failing treatment was calculated from 106 model runs, grouping the results into bins of width 20 ngmL−1. The blue
circles measure treatment failure as positive by microscopy on day 28: the orange triangles show results obtained when an additional follow-up is made on
day 42. b The simulated cumulative probability distribution for the time to recrudesce (the time at which parasitaemia becomes detectable by microscopy
after treatment failure) in our model. By day 28 (red vertical line), around 93% (black dashed line) of recrudescences are detectable. c Factors
inﬂuencing treatment failure. The probability of treatment failure according to patient body weight. The vertical red lines indicate the four dosing groups,
determining the number of pills per dose (one, two, three, or four). These results were generated by grouping patients into 2 kg-wide bins. The symbols are
as described in a
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Fig. 3 Model-estimated parasitological treatment failure rates at 28 days
after treatment with AL. Results for perfectly-adherent patients (6 doses)
are compared with patients who did not complete treatment. The bar
marked ‘5 doses’ denotes that only the ﬁrst 5 doses were taken, ‘4 doses’
that only the ﬁrst 4 were taken, and so on. In each case we performed
simulations for three body-weight distributions. For each bar shown, results
were obtained by simulating a cohort of 105 patients. Body-weight
distribution 1, taken from clinical trials of AL in African children6, was the
distribution used when ﬁtting the PD model (mean= 11.1 kg, SD 2.8). We
compare the results obtained in that case with two older cohorts:
distribution 2 (mean= 17.3 kg, SD= 6), and distribution 3 (mean= 30.0 kg,
SD= 10.0). All distributions were Gaussian, truncated so that the minimum
body weight was 5 kg
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regimen. To examine this, we simulated removal of doses one by
one, starting with the 6th dose, then removing the 5th and 6th,
and so on, assuming that the remaining doses were taken at the
recommended time. These simulations were carried out using
three different distributions for the patients’ body weight. The
estimated treatment failure rates clearly increase as doses are
removed (Fig. 3), for example, from 5.7% when 6 doses are taken
in the lowest body-weight group to 23% when only 4 doses are
taken. The missing doses always caused highest predicted failure
rates in the lowest body-weight group (mean= 11.1 kg, standard
deviation= 2.8 kg), for example 23% vs. 13% in the largest body-
weight group (mean= 30.0 kg, SD= 10.0) when 4 doses were
taken.
We examined the relative importance of doses in relation to
treatment failure in patients who took ﬁve timely doses, varying
which dose was missed. For example, missing the ﬁfth dose here
means taking the ﬁrst four doses at the recommended times, then
taking a further dose at the recommended time for the sixth dose.
Our results suggest that there was not a large difference in
treatment failure probability dependent on which dose was
missed. Missing the last dose was associated with a slightly higher
probability of failing treatment (0.12 vs. 0.10 for the ﬁfth dose,
0.093 for the fourth dose, 0.092 for the third dose and 0.088 for
the second dose). These results were obtained with the body-
weight distribution used to ﬁt the model (mean= 11.1 kg,
standard deviation= 2.8 kg).
We also assessed the importance of the timing of the 2nd dose,
since the recommended time interval between the ﬁrst and
second doses is only 8 h and therefore when a patient commences
treatment in the evening, the second dose will fall inconveniently
in the middle of the night. We found that delaying the second
dose by 4, 8, or 10 h did not lead to a raised probability of
parasitological treatment failure at 28 days, even if the subsequent
doses were also delayed. However, our model does not include
important relevant outcomes such as alleviation of symptoms and
prevention of hyperparasitaemia early in infection, which would
potentially be affected by such a delay.
To simulate realistic adherence patterns, we also utilised the
data collected in Tanzania in 2012 by Bruxvoort and colleagues,
who monitored patients taking AL treatment, in which tablets
were dispensed in smart blister packs. Microchips recorded the
time at which pills were removed for 659 patients (see ref. 36. for
details of the data collection and ethical approval for the original
study). These patients were largely unsupervised, although a
minority of patients reported taking their ﬁrst dose at the outlet
where treatment was obtained36. According to this data, 67% of
patients completed treatment, while 24% of patients took the
correct number of pills for each dose at the correct time (allowing
a tolerance of plus or minus four hours)36. We used these timings
as input for our simulation model, to determine when each pill
was taken. According to the data, 177 patients removed more pills
from the blister pack than was stipulated in a single dose. We
excluded these patients in our analysis, as our model does not
consider the ill-effects of taking large doses of pills (e.g., toxicity).
Equally, we do not know whether all the pills were taken at that
time or just removed from the blister pack for later use. We
therefore used the dose timings of 482 patients to estimate the
probability of treatment failure at 28 days associated with each
adherence proﬁle (doses taken and timings). Figure 4 shows two
subsets of the cohort with the lowest and highest estimated
probability of treatment failure, as predicted by the model
(Supplementary Fig. 4 displays results for all patients). Assessing
the cohort as a whole, we estimated a failure rate at 28 days of 9%
in these 482 patients. In comparison, a perfectly-adherent cohort
with this body-weight distribution (see caption of Fig. 4 for
details) has a failure rate of 4%. This 5% difference can be viewed
as a penalty due to imperfect adherence to treatment.
We looked for particular patterns of drug adherence that were
associated with an increased predicted risk in treatment failure
and tested a number of measures (Table 2). When analysing all
482 patients, including the number of doses taken and the
percentage of pills taken in the regression model explained much
of the variation in the failure rates. As these two variables were
strongly correlated, we included only the latter in the regression
model. However, variables for all doses being timely and whether
there was a long gap between doses did not improve the model ﬁt
and were not retained. We further assessed the impact of timely
dosing in the subset of patients who took all pills prescribed in the
correct number of doses. Including a variable for the sum of the
differences (in hours) between the recommended and actual dose
time for each patient indicated that, taking doses early was
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Fig. 4 The time series data recorded by the smart blister packs in ref. 36.
and model-estimated probability of parasitological treatment failure at day
28. Each row represents a patient, with each dose taken marked by a
rectangle. Shorter rectangles indicate that the patient did not take the full
dose. The rectangles are coloured to indicate the percentage of prescribed
pills taken by the patient: all pills (black) between 80–99% (cyan), 60–79%
(purple), 40–59% (orange), 20–39% (magenta), and <20% (brown). The
vertical, red lines indicate the recommended timings of the six doses. For
patients who took multiple pills per dose, we have grouped pills into doses
if pills were taken within half an hour of each other. In this ﬁgure, patients
are ordered by the probability that their adherence proﬁle results in
treatment failure, according to our within-host model. As the full cohort is
large (482 patients), we show two subsets here: the 80 patients with the
lowest failure probability (lower panel) and the 80 with the highest failure
probability (upper panel). The probability of failing treatment was
estimated from 104 simulations of the within-host model for each patient
adherence proﬁle. The body-weight data, which is needed to inform the PK
model, were not available for this cohort, however, the dosing group (the
number of pills per dose) is known. Therefore, when running our simulation
model for each patient, we average over the weight range (e.g. 5–15 kg for
the 1 pill per dose group) using a uniform probability distribution. Doses
taken after 75 h are not shown here, but their effects are included in the
model. The plot for all 482 patients is shown in Supplementary Fig. 4
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predicted to give lower treatment failure probabilities than when
doses were taken later. All doses being timely was also associated
with lower treatment failure probability, whereas a categorical
variable for having a long gap between doses did not improve the
model ﬁt.
Discussion
In this work, we have combined a within-host model of a
P. falciparum infection with the individual-level data on patient
adherence to AL in Tanzania to estimate the impact of sub-
optimal adherence on treatment outcomes. Importantly, the
adherence data were collected from patients in routine health care
settings. Using our within-host model, we estimate a treatment
failure rate of 9% in this cohort of Tanzanian patients, which is
higher than the failure rate of 4% predicted for this cohort had
adherence to treatment been optimal. In future work, we aim to
assess the impact that the increase in treatment failure rates has
on onward transmission and the return of clinical symptoms.
Our results emphasise the importance of considering the large
variation between patients in parasite dynamics and PKs. As
known from clinical trials, full adherence to AL still leads to
treatment failure in ~5% of patients. Our model matches well to
the clinical trial data, indicating that low drug concentrations are
a predictor of treatment failure. In a large pooled analysis of data
from patients treated with AL, recrudescence was associated with
low day-7 LMF concentrations and observed drug concentrations
were lowest in very young children35. Conversely, in other
patients, our results suggest that perfect adherence is not always
required to successfully clear parasites. Using a model enabled us
to quantify which aspects of adherence may be most important.
Our results suggest that missing doses leads to higher percentage
increases in treatment failure in younger patients, which under-
lines the fact that advice given to caregivers is very important.
As for other antimalarials, measures of adherence to AL show
widely-varying results. In a recent review of studies of adherence
to antimalarials9, levels of adherence to AL varied from 38.7 to
100%, reﬂecting variation in patient adherence, but also differing
deﬁnitions of being adherent to treatment. Clinical studies where
treatment of AL was unsupervised show a range of results, with
treatment failure ranging from rates similar to those observed in
trials (~5% e.g., refs. 10,13) to much higher levels (up to 20% e.g.,
refs. 11,37). Our model-predicted failure rate of 9% in the Tan-
zanian cohort therefore falls within a plausible range. The
variability in outcomes in these studies probably reﬂects differ-
ences in levels of adherence to treatment, although this was not
assessed in the studies. Variation in immunity is also likely to
have affected these outcomes. Two factors not included in our
model due to lack of data that may explain imperfect adherence
are early abatement of clinical symptoms and adverse side effects
to the drugs. Unless these are signiﬁcantly associated with para-
sitaemia and immunity (this may be the case for the former, but
we do not expect it to be so for the latter), they should not
affect our conclusions. After ACT treatment of uncomplicated
malaria, symptom resolution is rapid (typically about 1 day,
see e.g., ref. 38), and precedes complete clearance of parasites.
The modelling framework we have developed here could also
be applied to other antimalarial drugs or candidate compounds in
development (when the pharmacodynamics are characterised).
The ﬁrst step in the project was to develop a simple model of an
untreated infection episode of falciparum malaria. While a
number of similar models exist, many of these have a high level of
complexity21,24,25,30 and, as a result, are more computationally
expensive. This is largely due to the details of the antigenic
variation employed by the parasite, which presents a moving
target to the human immune system, prolonging the duration of
the infection. Here we were able to reduce the complexity to
a one-equation model that is informed by the effects of the
antigenic variation without modelling it explicitly, retaining good
ﬁdelity to the malaria therapy data set. This simplicity improves
computational efﬁciency and hence has wider potential for
integration into other frameworks.
It is important to note that the majority of malaria therapy
patients, against whom we calibrated our model, had had no prior
exposure to the P. falciparum parasite. This means that their
adaptive immune response was generated solely in response to
the malaria infection recorded in the dataset. Our model is
therefore most relevant to individuals with little previous expo-
sure, such as in low transmission settings. Other limitations of the
model are that we did not include clinical treatment failure nor
progression to severe malaria as outcomes, due to uncertainty
over how and when these outcomes are triggered. We also did not
include drug toxicity, which could arise, for example, when doses
are taken too close together. Therefore, the model results
suggesting that earlier dosing may reduce treatment failure
rates could be misleading. Other issues also affect adherence to
treatment such as drug side effects and vomiting a dose. Our
model was ﬁtted to match treatment outcomes found for a trial
in which AL was given with fatty foods, which increases the
bioavailability of lumefantrine39. Here we did not include the
possibility that patients did not take the drug with food, which
could provide an avenue for future work.
One modelling choice we had to make, for both treated and
untreated infections, was to decide at what density of para-
sitaemia indicates that the malaria infection has been cleared. As
mentioned in the ‘Methods’ section, we chose the density
105 PRBCs μL1, in line with other published within-host
models. Varying this cut off will inﬂuence the proportion of
infections that will be cleared by a course of AL. With the current
cutoff we observe a failure rate of 5.7% in the cohort used to ﬁt
the model while, for example, a cutoff of 104:5 PRBCs μL1
results in a rate 4.2%, and a cutoff of 105:5 PRBCs μL1 leads to a
rate of 7.8%. Due to the inability to probe such low parasite
densities in patients’ blood and to assess the numbers of
Table 2 Regression analysis of model results
Variable Odds ratio 95% conﬁdence interval p-value
Population model (n= 482)
Proportion of prescribed pills taken 0.00971 (0.00738,0.0128) <0.0001
Subset Model (n= 305)
Sum of [Actual minus recommended dose time] (in hours) 1.009 (1.007,1.012) <0.0001
All Doses Timely 0.827 (0.731,0.936) 0.003
Predictors of treatment failure (measured at day 28) in our simulation model, based on patterns of adherence found in the individual-level data. Regression was performed using logit-transformed
predicted treatment failure probability as the outcome. In model A all 482 patients were considered. A long gap between doses (>24 h) and all doses being timely (within 4 h of the recommended time)
did not improve the model ﬁt and were discarded. In Model B, we only assessed patients who had taken all prescribed pills in six doses. The categorical variable for a long gap between doses did not
improve the model ﬁt
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sequestered parasites, it is unclear what the appropriate cut off
should be, and indeed whether it is most appropriate to base it on
total parasite numbers in a person, or a speciﬁc concentration in
the blood. Longitudinal studies of patients using sensitive mole-
cular methods such as qPCR would help to deﬁne if there is a low
parasite concentration after which the parasite population is
always cleared.
The advantage of a many-dose antimalarial regimen— allowing
drug concentration to remain at effective levels for a long period
of time— should be offset against the fact that a regimen with
extra doses may lead to poorer adherence in unsupervised
treatment settings. The effectiveness of unsupervised treatment as
well as efﬁcacy in clinical trials must be considered when com-
paring antimalarial treatments with differing dose regimens. All
efforts must be made to ensure that patients understand the
details of treatment regimens and the importance of completing
treatment, both for ensuring optimal clinical outcomes for the
individual, as well as minimising the duration of parasitaemia and
onward transmission of the parasite.
Methods
Within-host model of an untreated infection. We build upon a model originally
proposed by Molineaux et al.21. and extended by Johnston et al.30. An important
aspect of these models is the inclusion of the antigenic variation displayed by the
parasite during an infection. A key target for the immune response is the protein
PfEMP1, encoded by the P. falciparum var genes and expressed on the surface of a
parasitised red blood cell (PRBC)28,29. This protein helps the parasites adhere to
blood vessels to avoid clearance by the spleen. A small percentage of parasites
switch their var expression each generation, presenting a moving target for the
human immune system and lengthening the duration of an untreated infection.
The published model describes the time evolution of 50 var variants during a single
P. falciparum infection. Using the subscript i to denote the variant being expressed,
the model is written in terms of the number of parasitised red blood cells (PRBCs)
per μL, Pi(t):
Pi t þ 1ð Þ ¼ mi Sc tð ÞSi tð ÞSm tð Þ½ Pi tð Þ; i ¼ 1; 2; ¼ ; 50 ð1Þ
Here mi is the (constant) growth rate of variant i. This discrete-time model has a
time-step of 48 h, reﬂecting the parasite’s erythrocytic life span. Over the 48-h
cycle, the PRBC spends part of its time in the blood stream, and the rest of the time
adhering to blood vessel walls. Observation of a patient’s blood during this period
can show variation in the parasite density measured, depending on the proportion
of parasites in the blood at a given time i.e. how synchronised the parasites’ life
cycles are40. One advantage of a 48-h time step is to discard this variation. In this
published model, the immune response is described by three functions: the innate
(or fever) response, ScðtÞ; the adaptive response, divided into var-speciﬁc responses
SiðtÞ (deﬁned separately for each variant i); and a general adaptive response, SmðtÞ,
which acts against targets conserved across the variants. Total asexual parasite
density is then deﬁned as the sum of the parasite densities across all variants, PiðtÞ.
Variant diversity is generated by introducing a small probability of switching from
variant i to another variant at each time step. In the published model, the innate
response depends simply on the current parasite density, whereas the adaptive
immune functions depend on a weighted history of parasite density, designed to
reﬂect a time-delayed adaptive immune response generating antibodies, which then
subsequently wane over time.
Using this framework as a starting point, we sought to develop a model with
only one equation for the total asexual parasitaemia:
P t þ 1ð Þ ¼ m tð Þ Sc tð ÞSv tð ÞSm tð Þ½ P tð Þ; ð2Þ
where mðtÞ represents the average growth rate of all the variants. Following
the model outlined above, we deﬁne the beginning of the infection as Pðt ¼ 1Þ ¼
0:1 PRBCs μL1 and deem an infection to have been cleared when parasitaemia
falls below 105 PRBCs μL1 (about 50 parasites in total in the blood volume of an
adult male). We retain the original form of the immune functions ScðtÞ and SmðtÞ:
Sc tð Þ ¼ 1
1þ P tð ÞPc
 κc ; ð3Þ
Sm tð Þ ¼ 1 β
1þ
Pt4
τ¼0 Pc τð Þ
Pm
 κm þ β; where Pc τð Þ ¼
PðτÞ if P τð Þ  C
C if P τð Þ>C

: ð4Þ
However we replace the var-speciﬁc immunity functions SiðtÞ with an immune
response SvðtÞ that we term the effective var-speciﬁc response (EVSR). This is
equivalent to describing the average efﬁcacy of the var-speciﬁc immune responses
at a particular time. The efﬁcacy of this immune response depends on which
variants are present at a given time and on the previous exposure of the immune
system to these variants. Here we do this by giving SvðtÞ a memory of past
parasitaemia, the duration of which will increase over the course of the infection.
This effect is represented by the function f ðtÞ, such that
SvðtÞ ¼ 1
1þ
Pt4
τ¼f ðtÞ P τð Þ
Pv 
 κv : ð5Þ
More detail on the motivation of the form of SvðtÞ can be found in the
Supplementary Methods and we illustrate the EVSR in Supplementary Fig. 1.
Capturing the growth rate of the parasite population. In variant-speciﬁc
models, the var variants grow at differing rates and the overall growth rate of the
asexual parasitaemia is an average of the growth rates of the subpopulations pre-
sent at any given time. In the data set, the log-transformed value of the initial slope
of the parasite growth has a wide range (Table 1), reﬂecting a variety of growth
rates early in the infections. Therefore, our effective growth rate, mðtÞ, should vary
according to an appropriate probability distribution. However, it should also vary
with time, as variants emerge and are subsequently removed from the infection.
We found that the best results are obtained when the growth rate at any one
time is drawn from a probability distribution, but also positively correlated with the
growth rate in the previous time step. This makes sense intuitively: after entering
the parasite population, a var variant typically remains present in the infection for a
number of generations before being cleared, contributing to the average growth
rate over this time. As the percentage of merozoites that switch their var expression
per generation is low, the average growth rate at time t should be positively
correlated with the average growth rate at t + 1. More formally, using angled
brackets to denote the average or expected value, we write
m  N μ; σð Þ; m tð Þ  μð Þ m t þ θð Þ  μð Þh i
σ2
¼ gθ; 0< g < 1: ð6Þ
Hence, the growth rates at time t and t + 1 are positively correlated with
correlation g. As in refs. 21,30. We truncate the distribution at 1 and 35, thus
limiting the minimum and maximum possible growth rates of the variants.
The model was ﬁtted to summary statistics from the malariatherapy data set
(Table 1), using Markov chain Monte Carlo methods to generate random walks in
parameter space. See Supplementary Methods for full details of model ﬁtting. The
parameters varied in the MCMC analysis were σ, g, km , Pv , as well as the parameter
that characterises the function f ðtÞ in Eq. 3. The best ﬁt parameters are shown in
Supplementary Table 1. In order to ﬁt the data, we had to strengthen the general-
adaptive immune response, which means that the balance between the two adaptive
responses has changed compared to the previous models.
The pharmacokinetic and pharmacodynamic models. We utilised a published
pharmacokinetic model by Hodel et al., ﬁtted to the data from patients in Tanzania
treated with AL following clinical episodes of uncomplicated falciparum malaria31.
Following the ﬁrst dose, subsequent doses are administered at 8, 24, 36, 48, and
60 h. Each tablet contains 20 mg of artemether (AM) and 120 mg of lumefantrine
(LMF), with the doses determined by the patient’s weight: 5–15 kg: one tablet per
dose; 15–25 kg: two tablets per dose; 25–35 kg: three tablets per dose; > 35 kg: four
tablets per dose3. Supplementary Fig. 2 shows the blood concentrations of the
drugs and their metabolites, including the population-level variation.
The pharmacodynamic component of the model determines the rate at which a
drug kills parasites, as a function of its concentration. Following other analyses19,20
we write this effect as
dP
dt
¼ kmax C tð ÞC tð Þ þ C50
 
P: ð7Þ
The drug effect saturates at high concentrations, with a maximum kill rate of
kmax. The concentration at which the maximum drug effect is halved is denoted by
C50. In other modelling work a Hill-coefﬁcient has been added to this equation e.g.,
ref. 16. However, without detailed time-series information on the effects the drugs
have on the parasitaemia, it is difﬁcult to determine this coefﬁcient. Therefore, here
we set it equal to one.
Since we have two drugs and two metabolites, we could in theory attempt to ﬁt
these two parameters for all of quantities, which would mean eight PD parameters
in total. However, with the data at hand, it would be impossible to uniquely
determine all these parameters. Therefore, we take steps to reduce the parameter
space, ﬁrstly by giving AM and DHA common values for the parameters kmax and
C50. Also, it is clear from the PK modelling that the concentration of metabolite —
DLF (Supplementary Fig. 2) is much lower than that of LMF. We will assume that
the dominant effect comes from the LMF, and ignore the PD properties of DLF41,
meaning that the contribution of the partner drug is only represented through the
concentration of LMF. This may have the effect of slightly overestimating the
killing rate of LMF, but we do not expect this effect to be very large.
From a large, multi-centred study of ACTs in African children6, we selected
clinical trial results from Ndola in Zambia against which to calibrate our
pharmacodynamic model. This site was chosen due to the low malaria prevalence
observed over the timespan of the trial4. As our model of the parasitaemia is ﬁtted
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to the data in patients with no prior exposure to the parasite, we expect our model
to be most relevant in low transmission settings. At this site, 71 out of 75 patients
were parasite negative 28 days after treatment commenced, once new infections
had been accounted for by PCR6. This gives a treatment success rate of nearly 95%.
This is consistent with AL success rates observed in the other trial sites, as well as in
other studies5,6. Our PD model, then, should be consistent with this success rate.
However, we found that this alone was not sufﬁcient to constrain the PD
parameters. We augmented this information with the percentage of patients who
were parasite positive one day after treatment commenced. Using these two
statistics, we simulated cohorts of 75 patients with a body-weight distribution to
match the Ndola cohort (normally distributed with mean and standard deviation of
11.1 and 2.8 kg, respectively). Simulating a large ensemble of cohorts generates a
distribution of values for the two target statistics, due the stochastic nature of the
model. The likelihood cannot be calculated explicitly from our stochastic
simulation model. However, we constructed a so-called pseudo likelihood, using
repeated stochastic simulation for each set of model parameters42. In addition, we
used estimates of the parasite reduction ratio43, along with in vitro estimates of the
drugs’ properties44–46 to constrain the parameters. The results from the studies on
recrudescence35 and reinfection47 following treatment with AL were led us to
require that C50>100 ng mL−1 for LMF. The best-ﬁt PD parameters for LMF were
kmax ¼ 0:165 h−1 and C50 ¼ 125 ng mL−1, and for artemether (and metabolite
DHA) kmax ¼ 0:189 h−1 and C50 ¼ 3:3 ng mL−1. Details of how the parasitaemia,
PK, and PD models were combined can be found in the Supplementary Methods
and in Supplementary Fig. 3.
Ethics statement. All the data analysis conducted during this research was sec-
ondary and used studies that had obtained ethical approval previously from the
appropriate organizations. All the data were anonymised before being provided to
investigators.
Data availability. The source code for the within-host model can be found at:
http://github.com/JDChallenger/adherence_project. The individual-level adherence
data for the Tanzanian cohort can be accessed through the ACTc Publications
Datasets Repository at http://actc.lshtm.ac.uk.
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